Myocardial Infarction Clinical Presentation: History …

Posted: Published on September 25th, 2018

This post was added by Jill Anderson

[Guideline] Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23. 130 (25):e344-426. [Medline]. [Full Text].

[Guideline] O'Gara PT, Kushner FG, Ascheim DD, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 Jan 29. 127 (4):e362-425. [Medline]. [Full Text].

[Guideline] Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14. 37 (3):267-315. [Medline]. [Full Text].

[Guideline] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC); Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012 Oct. 33 (20):2569-619. [Medline]. [Full Text].

Costa e Silva R, Pellanda L, Portal V, Maciel P, Furquim A, Schaan B. Transdisciplinary approach to the follow-up of patients after myocardial infarction. Clinics (Sao Paulo). 2008 Aug. 63 (4):489-96. [Medline].

Rathore SS, Gersh BJ, Weinfurt KP, Oetgen WJ, Schulman KA, Solomon AJ. The role of reperfusion therapy in paced patients with acute myocardial infarction. Am Heart J. 2001 Sep. 142(3):516-9. [Medline].

Jaffe AS. Third universal definition of myocardial infarction. Clin Biochem. 2013 Jan. 46 (1-2):1-4. [Medline].

Bonaca MP, Wiviott SD, Braunwald E, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation Universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the TRITON-TIMI 38 Trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38). Circulation. 2012 Jan 31. 125(4):577-83. [Medline].

Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012 Oct 16. 60 (16):1581-98. [Medline].

Fujita M, Nakae I, Kihara Y, et al. Determinants of collateral development in patients with acute myocardial infarction. Clin Cardiol. 1999 Sep. 22 (9):595-9. [Medline].

Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. 2013 Jul 23. 128 (4):388-400. [Medline].

Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007 Sep 13. 357 (11):1121-35. [Medline].

Marban E. Myocardial stunning and hibernation. The physiology behind the colloquialisms. Circulation. 1991 Feb. 83 (2):681-8. [Medline].

McGill HC Jr, McMahan CA, Zieske AW, et al. Associations of coronary heart disease risk factors with the intermediate lesion of atherosclerosis in youth. The Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb Vasc Biol. 2000 Aug. 20 (8):1998-2004. [Medline].

Kolodgie FD, Virmani R, Burke AP, et al. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004 Dec. 90 (12):1385-91. [Medline].

Soares AAS, Tavoni TM, de Faria EC, Remalay AT, Maranhao RC, Sposito AC, et al. HDL acceptor capacities for cholesterol efflux from macrophages and lipid transfer are both acutely reduced after myocardial infarction. Clin Chim Acta. 2018 Mar. 478:51-6. [Medline].

Holmes MV, Millwood IY, Kartsonaki C, et al, for the China Kadoorie Biobank Collaborative Group. Lipids, lipoproteins, and metabolites andrisk of myocardial infarction andstroke. J Am Coll Cardiol. 2018 Feb 13. 71 (6):620-32. [Medline]. [Full Text].

Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007 Jun 26. 49(25):2379-93. [Medline].

Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004 Jul 20. 110(3):278-84. [Medline].

Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995 Aug 1. 92(3):657-71. [Medline].

McDaniel MC, Willis P, Walker B, et al. Plaque necrotic core content is greater immediately distal to bifurcations compared to bifurcations in the proximal lad of patients with CAD. Am J Cardiol. 2008. 102(8):242i.

Yusuf S, Hawken S, Ounpuu S, et al, for the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004 Sep 11-17. 364 (9438):937-52. [Medline].

Macintyre CR, Heywood AE, Kovoor P, et al. Ischaemic heart disease, influenza and influenza vaccination: a prospective case control study. Heart. 2013 Dec. 99 (24):1843-8. [Medline].

Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018 Jan 25. 378 (4):345-53. [Medline]. [Full Text].

Concheiro-Guisan A, Sousa-Rouco C, Fernandez-Santamarina I, Gonzalez-Carrero J. Intrauterine myocardial infarction: unsuspected diagnosis in the delivery room. Fetal Pediatr Pathol. 2006 Jul-Aug. 25(4):179-84. [Medline].

Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J. 2008 Dec. 156 (6):1026-34. [Medline].

Lloyd-Jones D, Adams RJ, Brown TM, et al, for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23. 121 (7):948-54. [Medline].

Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world. Heart. 2002 Aug. 88 (2):119-24. [Medline].

Critchley J, Liu J, Zhao D, Wei W, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation. 2004 Sep 7. 110 (10):1236-44. [Medline].

Reddy KS. Cardiovascular disease in non-Western countries. N Engl J Med. 2004 Jun 10. 350 (24):2438-40. [Medline].

Okrainec K, Banerjee DK, Eisenberg MJ. Coronary artery disease in the developing world. Am Heart J. 2004 Jul. 148 (1):7-15. [Medline].

Ezzati M. How can cross-country research on health risks strengthen interventions? Lessons from INTERHEART. Lancet. 2004 Sep 11-17. 364 (9438):912-4. [Medline].

Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000 Aug 16. 284(7):835-42. [Medline].

Jaber WA, Prior DL, Marso SP, Houghtaling PL, Menon V, Harrington RA. CHF on presentation is associated with markedly worse outcomes among patients with acute coronary syndromes: PURSUIT trial findings. Circulation 1999:100(suppl I):I-433 .

Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967 Oct. 20(4):457-64. [Medline].

James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003 Jul 22. 108 (3):275-81. [Medline].

de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001 Oct 4. 345 (14):1014-21. [Medline].

Haaf P, Reichlin T, Corson N, et al. B-type natriuretic peptide in the early diagnosis and risk stratification of acute chest pain. Am J Med. 2011 May. 124 (5):444-52. [Medline].

Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998 Jun. 31 (7):1460-5. [Medline].

Boggs W. Worse Prognosis for Myocardial Infarction Patients With ST-Deviation in AVR. Medscape. Jul 11 2013. [Full Text].

Alherbish A, Westerhout CM, Fu Y, et al. The forgotten lead: does aVR ST-deviation add insight into the outcomes of ST-elevation myocardial infarction patients?. Am Heart J. Jul 3 2013. [Full Text].

Lee KL, Woodlief LH, Topol EJ, et al, for the GUSTO-I investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995 Mar 15. 91 (6):1659-68. [Medline].

[Guideline] Smith SC Jr, Allen J, Blair SN, et al,. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16. 113 (19):2363-72. [Medline]. [Full Text].

Mann DL, Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwalds Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Philadelphia, PA: Elsevier Saunders; 2015.

Wijnbergen I, Van't Veer M, Pijls NH, Tijssen J. Circadian and weekly variation and the influence of environmental variables in acute myocardial infarction. Neth Heart J. 2012 Sep. 20 (9):354-9. [Medline].

Kundi H, Kiziltunc E, Korkmaz A, Cicek G, Ornek E, Ileri M. A novel risk scoring system to predict cardiovascular death in patients with acute myocardial infarction: CHA2DS2-VASc-CF score. Clin Appl Thromb Hemost. 2018 Mar. 24 (2):273-8. [Medline].

Kacprzak M, Kidawa M, Zieliska M. Fever in myocardial infarction: is it still common, is it still predictive?. Cardiol J. 2012. 19 (4):369-73. [Medline].

Rise C, Kirkeby OJ, Grttum P, Sederholm M, Kjekshus JK. Fever after acute myocardial infarction in patients treated with intravenous timolol or placebo. Br Heart J. 1987 Jan. 57 (1):28-31. [Medline].

Patel MR, Mahaffey KW, Armstrong PW, Weaver WD, Tasissa G, Hochman JS, et al. Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL Trial). Am J Cardiol. 2005 Mar 1. 95 (5):614-8. [Medline].

Lee-Lewandrowski E, Januzzi JL Jr, Grisson R, Mohammed AA, Lewandrowski G, Lewandrowski K. Evaluation of first-draw whole blood, point-of-care cardiac markers in the context of the universal definition of myocardial infarction: a comparison of a multimarker panel to troponin alone and to testing in the central laboratory. Arch Pathol Lab Med. 2011 Apr. 135 (4):459-63. [Medline].

Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2009 Jul. 55 (7):1303-6. [Medline].

Diercks DB, Peacock WF 4th, Hollander JE, et al. Diagnostic accuracy of a point-of-care troponin I assay for acute myocardial infarction within 3 hours after presentation in early presenters to the emergency department with chest pain. Am Heart J. 2012 Jan. 163 (1):74-80.e4. [Medline].

Takakuwa KM, Ou FS, Peterson ED, et al. The usage patterns of cardiac bedside markers employing point-of-care testing for troponin in non-ST-segment elevation acute coronary syndrome: results from CRUSADE. Clin Cardiol. 2009 Sep. 32 (9):498-505. [Medline].

Mueller C. Biomarkers and acute coronary syndromes: an update. Eur Heart J. 2014 Mar. 35 (9):552-6. [Medline].

Anderson JL, Adams CD, Antman EM, et al, for the ACC, AHA Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the management of patients with unstable angina/NSTEMI, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interv... Circulation. 2007 Aug 14. 116 (7):e148-304. [Medline].

Reichlin T, Irfan A, Twerenbold R, et al. Utility of absolute and relative changes in cardiac troponin concentrations in the early diagnosis of acute myocardial infarction. Circulation. 2011 Jul 12. 124(2):136-45. [Medline].

Storrow AB, Nowak RM, Diercks DB, et al. Absolute and relative changes (delta) in troponin I for early diagnosis of myocardial infarction: Results of a prospective multicenter trial. Clin Biochem. 2015 Mar. 48 (4-5):260-7. [Medline].

Storrow AB, Christenson RH, Nowak RM, et al. Diagnostic performance of cardiac troponin I for early rule-in and rule-out of acute myocardial infarction: Results of a prospective multicenter trial. Clin Biochem. 2015 Mar. 48 (4-5):254-9. [Medline].

Cullen L, Parsonage WA, Greenslade J, et al. Delta troponin for the early diagnosis of AMI in emergency patients with chest pain. Int J Cardiol. 2013 Oct 3. 168 (3):2602-8. [Medline].

Thygesen K, Mair J, Mueller C, et al, for the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012 Aug. 33 (16):2001-6. [Medline].

Goldstein JA, Chinnaiyan KM, Abidov A, et al, for the CT-STAT Investigators. The CT-STAT (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment) trial. J Am Coll Cardiol. 2011 Sep 27. 58 (14):1414-22. [Medline].

Samad Z, Hakeem A, Mahmood SS, et al. A meta-analysis and systematic review of computed tomography angiography as a diagnostic triage tool for patients with chest pain presenting to the emergency department. J Nucl Cardiol. 2012 Apr. 19 (2):364-76. [Medline].

Cremer PC, Khalaf S, Agarwal S, et al. Myocardial perfusion imaging in emergency department patients with negative cardiac biomarkers: yield for detecting ischemia, short-term events, and impact of downstream revascularization on mortality. Circ Cardiovasc Imaging. 2014 Nov. 7 (6):912-9. [Medline].

Amgen Inc. FDA approves Amgen's Repatha (evolocumab) to prevent heart attack and stroke [press release]. Available at https://www.amgen.com/media/news-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke/. December 1, 2017; Accessed: December 7, 2017.

Sabatine MS, Giugliano RP, Keech AC, et al, for the FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4. 376 (18):1713-22. [Medline]. [Full Text].

Becker L, Larsen MP, Eisenberg MS. Incidence of cardiac arrest during self-transport for chest pain. Ann Emerg Med. 1996 Dec. 28 (6):612-6. [Medline].

Mathews R, Peterson ED, Li S, et al. Use of emergency medical service transport among patients with ST-segment-elevation myocardial infarction: findings from the National Cardiovascular Data Registry Acute Coronary Treatment Intervention Outcomes Network Registry-Get With The Guidelines. Circulation. 2011 Jul 12. 124 (2):154-63. [Medline].

[Guideline] Jneid H, Addison D, Bhatt DL, et al. 2017 AHA/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol. 2017 Oct 17. 70 (16):2048-90. [Medline].

Wendling P. AHA/ACC issue new performance, quality measures for MI. Medscape Medical News. Available at https://www.medscape.com/viewarticle/886075. September 22, 2017; Accessed: March 26, 2018.

[Guideline] Ibanez B, James S, Agewall S, et al, for the ESC Scientific Document Group . 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018 Jan 7. 39 (2):119-77. [Medline]. [Full Text].

Cabello JB, Burls A, Emparanza JI, Bayliss S, Quinn T. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev. 2013 Aug 21. 8:CD007160. [Medline].

Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006 Jun 27. 113 (25):2906-13. [Medline].

Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000 Jul 5. 284 (1):60-7. [Medline].

De Luca G, Suryapranata H, Ottervanger JP, Antman EM. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004 Mar 16. 109 (10):1223-5. [Medline].

Armstrong PW, Westerhout CM, Welsh RC. Duration of symptoms is the key modulator of the choice of reperfusion for ST-elevation myocardial infarction. Circulation. 2009 Mar 10. 119 (9):1293-303. [Medline].

Bates ER, Nallamothu BK. Commentary: the role of percutaneous coronary intervention in ST-segment-elevation myocardial infarction. Circulation. 2008 Jul 29. 118 (5):567-73. [Medline].

Ellis SG, Armstrong P, Betriu A, et al, for the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events Investigators. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J. 2004 Apr. 147 (4):E16. [Medline].

Andersen HR, Nielsen TT, Rasmussen K, et al, for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med. 2003 Aug 21. 349 (8):733-42. [Medline].

Widimsky P, Budesnsky T, Vorac D, et al, for the 'PRAGUE' Study Group Investigators. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2. Eur Heart J. 2003 Jan. 24 (1):94-104. [Medline].

Vaidya SR, Qamar A, Arora S, Devarapally SR, Kondur A, Kaul P. Culprit versus multivessel coronary intervention in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. Coron Artery Dis. 2018 Mar. 29 (2):151-60. [Medline].

Spitaleri G, Brugaletta S, Scalone G, et al. Role of ST-segment resolution in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention (from the 5-year outcomes of the EXAMINATION Trial) [in press]. Am J Cardiol. 7 Feb 2018. [Full Text].

Rencuzogullari I, Cagdas M, Karabag Y, et al. Association of the SYNTAX Score II with cardiac rupture in patients with ST-segment elevation myocardial infarction undergoing a primary percutaneous coronary intervention. Coron Artery Dis. 2018 Mar. 29 (2):97-103. [Medline].

Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994 Feb 5. 343 (8893):311-22. [Medline].

White HD. Thrombolytic therapy in the elderly. Lancet. 2000 Dec 16. 356 (9247):2028-30. [Medline].

Van de Werf F, Barron HV, Armstrong PW, et al, for the ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J. 2001 Dec. 22 (24):2253-61. [Medline].

Kodumuri V, Balasubramanian S, Vig A, et al. A meta-analysis comparing percutaneous coronary intervention with drug eluting stents versus coronary artery bypass grafting in unprotected left main disease [in press]. Am J Cardiol. 5 Feb 2018. [Full Text].

Yusuf S, Mehta SR, Chrolavicius S, et al, for the OASIS-6 Trial Group. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA. 2006 Apr 5. 295 (13):1519-30. [Medline].

Giraldez RR, Nicolau JC, Corbalan R, et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis. Eur Heart J. 2007 Jul. 28 (13):1566-73. [Medline].

Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003 Jul 15. 108 (2):135-42. [Medline].

Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 Aug 25. 358 (9282):605-13. [Medline].

White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet. 2001 Dec 1. 358 (9296):1855-63. [Medline].

Wiviott SD, Braunwald E, McCabe CH, et al, for the TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15. 357 (20):2001-15. [Medline].

Tcheng JE, Mackay SM. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. Am J Cardiovasc Drugs. 2012 Apr 1. 12 (2):83-91. [Medline].

Schnapf AJ. Prasugrel versus clopidogrel: new management strategies for acute coronary syndrome. J Cardiovasc Nurs. 2013 Sep-Oct. 28 (5):483-94. [Medline].

Ryan TJ. Percutaneous coronary intervention in st-elevation myocardial infarction. Curr Cardiol Rep. 2001 Jul. 3(4):273-9. [Medline].

Berger JS, Sallum RH, Katona B, et al. Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A systematic review of the literature. Am Heart J. 2012 Aug. 164 (2):153-162.e5. [Medline].

CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2. 363 (10):930-42. [Medline].

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16. 348 (9038):1329-39. [Medline].

Wallentin L, Becker RC, Budaj A,et al, for the PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10. 361 (11):1045-57. [Medline].

Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J. 2011 Dec. 32 (23):2945-53. [Medline].

View original post here:

Myocardial Infarction Clinical Presentation: History ...

Related Posts
This entry was posted in Myocardial Infarction. Bookmark the permalink.

Comments are closed.